The TRANSCEND NHL study, led by CU Cancer Center member Manali Kamdar, MD, and Rodrigo Leão Edelmuth, M.D., FACS, at Hospital Israelita Albert Einstein, shows that liso-cel CAR T-cell therapy provides lasting benefits for patients with relapsed or refractory large B-cell lymphoma. After five years, 38% of patients were alive, with those in complete remission reaching a 56% survival rate. Liso-cel modifies a patient’s immune cells to fight cancer more effectively, offering a potential cure for a disease that previously had poor long-term outcomes. Side effects were manageable, and most resolved within months, confirming liso-cel’s safety profile and curative potential